FIT Biotech Oy Company release, December 17, 2015 at 10:00am EET FIT BIOTECH OY FINANCIAL INFORMATION SCHEDULE AND AGM 2016 Deviating from its earlier announcement, FIT Biotech Oy will publish its financial statements release for 2015 already on March 11, 2016. FIT Biotech will report on its financials on the following dates in 2016: - Full-year financial statements release for 2015 on Friday, March 11, 2016 - Half-year interim report for January-June on Thursday, September 15, 2016 The ordinary annual general meeting of shareholders is planned for Friday, April 8, 2016. The company's Board of Directors will publish a separate notice to the AGM at a later date. FIT Biotech's annual report will be published on the company's website at www.fitbiotech.fi during calendar week 11 / 2016. FIT Biotech Oy More information: Kalevi Reijonen CEO, FIT Biotech Oy Telephone: +358 40 843 5695 kalevi.reijonen@fitbiotech.com Certified Advisor: Translink Corporate Finance Oy, telephone +358 20 743 2790 FIT Biotech Oy in brief: FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets a significant medical challenge in the usability of gene therapy and DNA vaccines. FIT Biotech presently applies the GTU® technology to seven drug development programmes. Examples of application areas include cancer (gene therapy), infectious diseases, such as HIV and tuberculosis, and animal vaccines. FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq OMX Helsinki Oy. DISTRIBUTION: Nasdaq OMX Helsinki Principal media www.fitbiotech.com
HUG#1974332